1-1 of 1
On behalf of the International Working Group on MDS with del5q
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study

Free
Andrea Kuendgen, MD, Michael Lauseker, Alan F. List, MD, Pierre Fenaux, MD, PhD, Aristoteles Giagounidis, MD, Nancy Brandenburg, PhD, Jay Backstrom, MD, Axel Glasmacher, MD, Joerg Hasford, MD, Ulrich Germing, MD, On behalf of the International Working Group on MDS with del5q
Journal: Blood
Blood (2011) 118 (21): 119.
https://doi.org/10.1182/blood.V118.21.119.119
Published: 2011